Journal Article Preprint Epublish 1 citation
PubMed: 40385398 DOI: 10.1101/2025.05.03.25326526
Pittsburgh plasma p-tau217: classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community.
medRxiv
Authors: Anuradha Sehrawat, Xuemei Zeng, Eric E Abrahamson, Rebecca A Deek, Alexandra Gogola, M Ilyas Kamboh, Tharick A Pascoal, Victor L Villemagne, Oscar L Lopez, Milos D Ikonomovic, Beth E Snitz, Ann D Cohen, Thomas K Karikari
Affiliations
- Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Geriatric Research Education and Clinical Center, VA Pittsburgh HS, Pittsburgh, PA, 15240, USA.
- Department of Biostatistics and Health Data Science, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.
- Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Abstract
INTRODUCTION
Most available p-tau217 immunoassays have similar performances. It is unclear if this is due to the use of the same antibody (the "ALZpath antibody"). We established and evaluated a novel p-tau217 assay that employs an alternative antibody, and benchmarked the results against ALZpath-p-tau217.
METHODS
Following development and analytical validation of the University of Pittsburgh ("Pitt-p-tau217") method, clinical verification was performed in three independent cohorts (n=363).
RESULTS
Pitt-p-tau217 demonstrated high between-run stability, linearity, and specificity. Clinically, Pitt-p-tau217 differentiated neuropathologically confirmed PSEN1 mutation carriers from controls with AUC=0.94, and Aβ-PET-positive from Aβ-PET-negative cognitively normal older adults with AUC up to 0.84, equivalent to ALZpath-p-tau217 results. Both Pitt-p-tau217 and ALZpath-p-tau217 were elevated in tau-PET-positive versus tau-PET-negative participants (P=0.06; AUC=0.71 for both). Between-assay correlations were up to 0.93.
DISCUSSION
The new Pitt-p-tau217 assay exhibits high and reproducible classification accuracies for identifying individuals with biological evidence of AD, equivalent to the widely used ALZpath-p-tau217.
MeSH
Alzheimer Disease, Classification, Plasma